MedTrace Logo

Effectiveness of Acyclovir in Suppressing HIV Viral Load in Women Coinfected With HIV and Herpes Simplex Virus Type 2 (HSV-2)

NCT00371592 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2013-09-23

No results posted yet for this study

Summary

The purpose of this study is to determine whether acyclovir is effective in suppressing HIV viral load in women infected with both HIV-1 and herpes simplex virus type 2 (HSV-2) who are starting HIV treatment for the first time.

Conditions

  • HIV Infections
  • Herpesvirus 2, Human

Interventions

DRUG

Acyclovir

800 mg tablet taken orally twice daily

DRUG

Acyclovir placebo

800 mg placebo tablet taken orally twice daily

Sponsors & Collaborators

  • Comprehensive International Program of Research on AIDS

    collaborator OTHER

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Aldo Lucchetti, MD · Asociación Civil Impacta Salud y Educación, Lima, Peru

  • Connie Celum, MD, MPH · University of Washington

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2009-01-31
Completion
2009-01-31

Countries

  • Peru

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00371592 on ClinicalTrials.gov